Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2019 221.07M
September 30, 2019 221.07M
June 30, 2019 221.06M
March 31, 2019 220.98M
December 31, 2018 220.84M
September 30, 2018 220.83M
June 30, 2018 220.80M
March 31, 2018 220.38M
December 31, 2017 220.14M
September 30, 2017 220.10M
June 30, 2017 219.96M
March 31, 2017 219.65M
December 31, 2016 219.33M
September 30, 2016 219.29M
June 30, 2016 219.24M
March 31, 2016 219.18M
December 31, 2015 219.13M
September 30, 2015 219.13M
June 30, 2015 219.11M
March 31, 2015 219.02M
December 31, 2014 218.96M
September 30, 2014 218.95M
June 30, 2014 218.94M
March 31, 2014 218.76M
December 31, 2013 218.66M
Date Value
September 30, 2013 218.66M
June 30, 2013 218.66M
March 31, 2013 218.38M
December 31, 2012 218.00M
September 30, 2012 217.92M
June 30, 2012 217.84M
March 31, 2012 217.84M
December 31, 2011 217.82M
September 30, 2011 217.82M
June 30, 2011 217.82M
March 31, 2011 217.75M
December 31, 2010 217.67M
September 30, 2010 217.54M
March 31, 2010 217.26M
December 31, 2009 217.20M
September 30, 2009 217.20M
June 30, 2009 217.20M
March 31, 2009 217.20M
December 31, 2008 217.20M
September 30, 2008 217.20M
June 30, 2008 217.17M
March 31, 2008 217.13M
December 31, 2007 217.13M
September 30, 2007 228.76M
June 30, 2007 228.75M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 3.102B
ANI Pharmaceuticals, Inc. 22.97M
Corcept Therapeutics, Inc. 107.92M
Veru, Inc. 17.05M
Avadel Pharmaceuticals Plc 97.24M